In this episode of The Beat, recorded at HLTH 2023, Dr. Gautam Gulati sits down with Dr. Megan Hall to discuss the future of cancer detection and prevention through early genetic testing.
In this groundbreaking era of healthcare, the opportunity to revolutionize cancer outcomes has never been more promising. With cutting-edge testing techniques, early detection strategies, and the power of AI, the landscape of cancer care is evolving to save lives and enhance patient well-being like never before.
In this episode of The Beat, Dr. Gautam Gulati sits down with Dr. Megan Hall to discuss the future of cancer detection and prevention through early genetic testing.
Dr. Megan Hall is the Vice President of Corporate Affairs at GRAIL. With a Ph.D. in microbiology, immunology, and molecular genetics she is dedicated to making early cancer detection and prevention accessible on a population scale.
As Dr. Hall says, “I was enamored of the mission to detect cancer early when it can be cured. That's a huge problem that we have to be frank have not made great headway on in the 50 years that we've been waging this war on cancer.”
Now she shares how GRAIL's flagship product, Galleri, is using advanced technology, including DNA methylation analysis and artificial intelligence (AI), to detect and predict cancer in a non-invasive way.
Listen in as we explore the potential cost savings and improved outcomes with early cancer detection, and GRAIL's efforts to make this transformative technology accessible to a broader population.
Topics Covered
Connect with Dr. Megan Hall
Connect with Dr. Gautam Gulati & Dr. Jessica Shepherd
Resources